Sign inJoin waitlistJoin the waitlist

Alicia Lenzen

Program Director, Pediatric Neuro-Oncology Fellowship · McGaw Medical Center of Northwestern University

Credentials: · · · ·

History

Pediatric Neuro-Oncology Fellowship · McGaw Medical Center of Northwestern University
Present
McGaw Medical Center of Northwestern University
Present
McGaw Medical Center of Northwestern University
Present

Pediatric Hematology/Oncology
McGaw Medical Center of Northwestern University
2015–2018
Pediatrics
Advocate Christ Medical Center
2011–2014
Warren Alpert Medical School of Brown University
2007–2011

Research

IDO1 in cancer: a Gemini of immune checkpoints
Review · Cellular and Molecular Immunology · 2018 · 355 citations
IDO1 Inhibition Synergizes with Radiation and PD-1 Blockade to Durably Increase Survival Against Advanced Glioblastoma
Clinical Cancer Research · 2018 · 185 citations
Phase I trial of panobinostat in children with diffuse intrinsic pontine glioma: A report from the Pediatric Brain Tumor Consortium (PBTC-047)
Neuro-Oncology · 2023 · 61 citations

JF
Jason Fangusaro
4 papers
David Binder
3 papers · 3 as a resident
Ira Dunkel
3 papers
Natasha Smiley
3 papers
Nathan Robison
3 papers
Nitin Wadhwani
3 papers
Amy Walz
2 papers · 1 as a fellow
Anna Vinitsky
2 papers
CC
Chantel Cacciotti
2 papers
Elliot Stieglitz
2 papers
Ian Pollack
2 papers
Lindsay Kilburn
2 papers

Clinical trials

A Study Comparing Two Carboplatin Containing Regimens for Children and Young Adults With Previously Untreated Low Grade Glioma
Principal investigator · Completed · Phase 3
Alicia Lenzen
2015–2025
Illuminate: A Clinical Study Evaluating CAR T Immune Cell Therapy (BCB-276) for Patients With Diffuse Intrinsic Pontine Glioma (DIPG).
Site PI · Recruiting · Phase 2
BrainChild Bio, Inc
2026–2030
A Study of Lower Radiotherapy Dose to Treat Children With CNS Germinoma
Site PI · Recruiting · Phase 2
Children's Oncology Group
2024–2033
A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT
Site PI · Recruiting · Phase 2
Children's Oncology Group
2021–2029